{"id":"NCT03250377","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","officialTitle":"An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-05","primaryCompletion":"2024-12-24","completion":"2024-12-24","firstPosted":"2017-08-15","resultsPosted":"2025-07-29","lastUpdate":"2025-07-29"},"enrollment":207,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Partial Seizures With or Without Secondary Generalization","Epilepsy"],"interventions":[{"type":"DRUG","name":"Brivaracetam","otherNames":["Briviact"]}],"arms":[{"label":"Brivaracetam","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From Baseline until end of the safety follow up (up to 88.5 months)","effectByArm":[{"arm":"EP0083 Placebo","deltaMin":88.9,"sd":null},{"arm":"EP0083 BRV All","deltaMin":95.5,"sd":null},{"arm":"N01379 BRV","deltaMin":100,"sd":null},{"arm":"Direct Enrollers BRV","deltaMin":94.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":59,"countries":["China","Japan"]},"refs":{"pmids":["40549270"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":54},"commonTop":["Corona virus infection","Nasopharyngitis","Pyrexia","Dizziness","Headache"]}}